Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Privitera

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Cell|February 16, 2024
GSDMB is increased in IBD and regulates epithelial restitution/repair independent of pyroptosisNitish Rana, Giuseppe Privitera, Hannah C Kondolf, et al.
Alimentary Pharmacology & Therapeutics|July 25, 2022
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Federica Crispino, et al.
Journal of Crohn'S & Colitis|December 23, 2025
Learning Curve in Intestinal Ultrasound: Advancing from Basic Skills to Advanced Competencies-Insights from the IUS IG-IBD Master ProgramCristina Bezzio, Luisa Bertin, Simone Saibeni, et al.
United European Gastroenterology Journal|November 18, 2020
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD studyDaniela Pugliese, Giuseppe Privitera, Francesca Rogai, et al.
La Radiologia Medica|February 27, 2019
Trends in combined radio-chemotherapy for locally advanced rectal cancer: a survey among radiation oncology centers of Sicily region on behalf of AIROCorrado Spatola, Giuseppe Privitera, Roberto Milazzotto, et al.
Tumori|March 29, 2014
Breast cancer bone metastases: an epidemiologic study in selected radiation departmentsRaffaele Runco, Simona Laganà, Giacomo Marino, et al.
Advances in Therapy|June 30, 2026
Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE StudyGiuseppe Privitera, Flavia Palumbo, Fabio Salvatore Macaluso, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 30, 2026
Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitisGiuseppe Privitera, Cristina Bezzio, Gisella Figlioli, et al.
Expert Opinion on Biological Therapy|December 14, 2021
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in ItalyAntonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 13, 2025
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Nicola Cersullo, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Cell|February 16, 2024
GSDMB is increased in IBD and regulates epithelial restitution/repair independent of pyroptosisNitish Rana, Giuseppe Privitera, Hannah C Kondolf, et al.
Alimentary Pharmacology & Therapeutics|July 25, 2022
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Federica Crispino, et al.
Journal of Crohn'S & Colitis|December 23, 2025
Learning Curve in Intestinal Ultrasound: Advancing from Basic Skills to Advanced Competencies-Insights from the IUS IG-IBD Master ProgramCristina Bezzio, Luisa Bertin, Simone Saibeni, et al.
United European Gastroenterology Journal|November 18, 2020
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD studyDaniela Pugliese, Giuseppe Privitera, Francesca Rogai, et al.
La Radiologia Medica|February 27, 2019
Trends in combined radio-chemotherapy for locally advanced rectal cancer: a survey among radiation oncology centers of Sicily region on behalf of AIROCorrado Spatola, Giuseppe Privitera, Roberto Milazzotto, et al.
Tumori|March 29, 2014
Breast cancer bone metastases: an epidemiologic study in selected radiation departmentsRaffaele Runco, Simona Laganà, Giacomo Marino, et al.
Advances in Therapy|June 30, 2026
Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE StudyGiuseppe Privitera, Flavia Palumbo, Fabio Salvatore Macaluso, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 30, 2026
Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitisGiuseppe Privitera, Cristina Bezzio, Gisella Figlioli, et al.
Expert Opinion on Biological Therapy|December 14, 2021
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in ItalyAntonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 13, 2025
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Nicola Cersullo, et al.
Pageof 10